Literature DB >> 2207657

Behavioural modification of bulbospinal serotonergic inhibition and morphine analgesia.

R J Milne1, G D Gamble.   

Abstract

Habituation to the stress of sham nociceptive testing enhances a rat's sensitivity to noxious thermal stimuli and reduces the antinociceptive effect of a subsequent acute dose of morphine. Since serotonin (5-hydroxytryptamine, 5-HT) mediates stress responses, experiments were designed to elucidate the role of 5-HT in these phenomena. Intrathecal methysergide or 5,7-dihydroxytryptamine (5,7-DHT) reduced baseline tail-flick latencies of novice rats to those of habituated animals. Morphine dose-response relationships were fitted to a 4 parameter sigmoidal function. Baseline latencies of novice animals were increased by 5-hydroxytryptophan (5-HTP) and reduced by parachlorophenylalanine (PCPA) in both reflex tests and in the hot-plate test, but latencies of habituated animals were unchanged by either treatment. In both reflex tests, the maximum effect due to morphine was increased by 5-HTP and reduced by PCPA in novice but not in habituated animals. We conclude that the serotonergic component of morphine's bulbospinal action represents the stress of the testing environment rather than an essential part of morphine's action.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2207657     DOI: 10.1016/0006-8993(90)91539-s

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  3 in total

1.  Activation of serotonergic neurons in the raphe magnus is not necessary for morphine analgesia.

Authors:  K Gao; D O Chen; J R Genzen; P Mason
Journal:  J Neurosci       Date:  1998-03-01       Impact factor: 6.167

2.  Entanglement between thermoregulation and nociception in the rat: the case of morphine.

Authors:  Nabil El Bitar; Bernard Pollin; Elias Karroum; Ivanne Pincedé; Daniel Le Bars
Journal:  J Neurophysiol       Date:  2016-09-07       Impact factor: 2.714

Review 3.  Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness.

Authors:  R J Milne; K L Goa
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.